Short answer: No studies tested BPC-157 and TB-500 together; both have almost no human data.
- FlagNo known interaction
- EvidenceNo human studies found
- Sources3
- Last reviewedOctober 22, 2026
What is known
No human studies of these two together were found. BPC-157's healing effects come mostly from animal studies; human data are three small, poor-quality studies. The FDA says it has found no human exposure data for TB-500 (a thymosin beta-4 fragment). No known interaction has been reported, but that reflects missing research, not proof of safety.
A 2025 systematic review found 35 preclinical studies and 1 clinical study of BPC-157 in musculoskeletal healing, and no clinical safety data. Human trials of thymosin beta-4 used the full-length recombinant protein, not the TB-500 fragment; a phase 1 trial of the full protein in healthy volunteers reported only mild to moderate side effects. On its page about compounding substances with possible safety risks, the FDA says both may cause immune reactions and raise concerns about impurities.
How strong the evidence is
No human studies found. We found no study of this pair in people and no specific reason to expect the two to interact. Each compound's own risks still apply. No known interaction: Nothing reported. For most peptides that is because the pair was never studied, so it means unknown, not safe.
Guides: BPC-157, TB-500. To check this pair alongside others, open it in the peptide interaction checker.
Education only, not medical advice. "No known interaction" means we found nothing reported, not that a combination is safe. Most of the peptides here are not FDA approved, and most pairs have never been studied together in people. Talk to your clinician or pharmacist before you start, stop or combine anything.
Sources
- Poolton JT, et al. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg, 2026. PMID 42885452
Found only 3 small human studies of BPC-157 (30 people total), all poor quality, with very low certainty of evidence.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA web page (content current as of 04/22/2026), 2026
Says FDA has not identified any human exposure data for thymosin beta-4 fragment (LKKTETQ, TB-500) and lacks information on whether it would cause harm in humans.
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J, 2025. PMID 40756949
Of 36 included studies on BPC-157, 35 were preclinical and 1 clinical; no clinical safety data were found.
Other reviewed pairs with BPC-157
Other reviewed pairs with TB-500